NCT01286207

Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)

Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Protocols 022, 025, 029)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,959 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This record describes pooled data for three extension studies: MK-0462-022 (NCT00897949); MK-0462-025 (NCT00899379); and MK-0462-029 (NCT00897104). These studies examined the long-term safety and efficacy of rizatriptan used for the treatment of acute migraine and migraine recurrence.

Conditions

• Migraine Disorders

Interventions

Type	Name	Description
DRUG	Rizatriptan 5 mg	Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
DRUG	Rizatriptan 10 mg	Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
DRUG	Standard Care	Active standard care

Timeline

• Start date: 1995-03-01
• Primary completion: 1997-05-01
• Completion: 1997-05-01
• First posted: 2011-01-31
• Last updated: 2022-02-03
• Results posted: 2011-06-10